Imaging

The Global Imaging Group focuses on understanding and evaluating the effect of drugs on disease models using a broad range of whole-body and microscopy-based imaging methods. Additionally, the group addresses the validation of biomarkers to follow disease progression.

Imaging allows for non-invasive assessment of disease conditions, drug efficacy, and safety read outs thus enabling us to reduce the number of animals used in an experiment. Our non-invasive imaging platform is partly based on the same methods used in clinical routine such as PET, CT and MRI allowing us to align preclinical research with patient studies.

The group also designs and uses a broad range of imaging probes to monitor molecular events in cells and organs with high specificity. These probes are either used for whole-body molecular imaging or microscopy on organs, tissue samples and cells.

The Global Imaging Group uses imaging techniques in animal studies for whole body imaging (PET, MRI, CT, and SPECT) and for optical imaging (bioluminescent probes) as well as performs cellular imaging.

 

Selected Publications

Optical imaging for the new grammar of drug discovery. Krucker T., Sandanaraj B.S., Philos Transac of the Royal Society, 2011 Nov 28;369(1955):4651-65.

Non-Invasive Assessment of Bleomycin-Induced Lung Injury and the Effects of Short Term Glucocorticosteroid Treatment in Rats Using MRI. A. L. Babin, C. Cannet, C. Gérard, D. Wyss, C. P. Page, and N. Beckmann. J. Magn. Reson. Imaging 33, 603-614 (2011).

Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability. Paul MJ McSheehy, Claudia Weidensteiner, Catherine Cannet, Stephane Ferretti, Didier Laurent, Stephan Ruetz, Michael Stumm & Peter R Allegrini. Clinical Cancer Research 16 (2010) 212-225